213 related articles for article (PubMed ID: 26960469)
1. Bortezomib in newly diagnosed patients with multiple myeloma: A retrospective analysis from a tertiary care center in India.
Pragnya C; Linga VG; Thota NK; Gundeti S; Digumarti R
Indian J Cancer; 2015; 52(4):537-40. PubMed ID: 26960469
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Tessenow H; Holzvogt M; Holzvogt B; Andrea M; Heyn S; Schliwa T; Schwarz M; Zehrfeld T; Becker C; Pfrepper C; Franke GN; Krahl R; Jentzsch M; Leiblein S; Schwind S; Bill M; Vucinic V; Lange T; Niederwieser D; Pönisch W
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2049-2058. PubMed ID: 28534173
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Shah G; Kaul E; Fallo S; Cossor F; Smith H; Sprague K; Klein A; Miller K; Comenzo R
Clin Ther; 2013 Oct; 35(10):1614-20. PubMed ID: 24075726
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation.
de Arriba de la Fuente F; Durán MS; Álvarez MÁ; Sanromán IL; Dios AM; Ríos Tamayo R; García R; González MS; Prieto E; Bárez A; Escalante F; Tejedor A; Ballesteros M; Cabañas V; Capote FJ; Couto C; Garzón S; González-Pardo M; Mateos Manteca MV
Semin Hematol; 2018 Oct; 55(4):189-196. PubMed ID: 30502846
[TBL] [Abstract][Full Text] [Related]
6. Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma.
Liapis K; Kastritis E; Bagratouni T; Vassiliou S; Papachristidis A; Charitaki E; Alevizopoulos N; Harhalakis N; Terpos E; Delimpasi S; Dimopoulos MA
J BUON; 2015; 20(5):1314-21. PubMed ID: 26537080
[TBL] [Abstract][Full Text] [Related]
7. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
9. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis.
Mu SD; Ai LS; Qin Y; Hu Y
Curr Med Sci; 2018 Feb; 38(1):43-50. PubMed ID: 30074150
[TBL] [Abstract][Full Text] [Related]
11. Real‑life experience with bortezomib‑based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study.
Hus I; Walter-Croneck A; Masternak A; Jurczyszyn A; Usnarska-Zubkiewicz L; Bołkun Ł; Druzd-Sitek A; Rymko M; Łętowska J; Lech-Marańda E; Pasiarski M; Dmoszyńska A
Pol Arch Intern Med; 2017 Nov; 127(11):765-774. PubMed ID: 28906482
[TBL] [Abstract][Full Text] [Related]
12. Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma.
Saraceni MM; Scott E; Maziarz RT; Siegel MB; Bassale S; Jiing S; Medvedova E
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e77-e84. PubMed ID: 29169873
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
14. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib plus thalidomide for newly diagnosed multiple myeloma in China.
Chen SL; Jiang B; Qiu LG; Yu L; Zhong YP; Gao W
Anat Rec (Hoboken); 2010 Oct; 293(10):1679-84. PubMed ID: 20734318
[TBL] [Abstract][Full Text] [Related]
17. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
Niesvizky R; Richardson PG; Rajkumar SV; Coleman M; Rosiñol L; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Boral AL; Esseltine DL; Anderson KC; Bladé J
Br J Haematol; 2008 Oct; 143(1):46-53. PubMed ID: 18673366
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
19. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Sezer O; Beksac M; Hajek R; Sucak G; Cagirgan S; Linkesch W; Meltem Akay O; Gülbas Z; Nahi H; Plesner T; Snowden JA; Timurağaoğlu A; Dechow T; Lang A; Tuğlular T; Drach J; Armbrecht G; Potamianou A; Couturier C; Olie RA; Feys C; Allietta N; Terpos E
Br J Haematol; 2017 Jul; 178(1):61-71. PubMed ID: 28382618
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.
Zheng W; Wei G; Ye X; He J; Li L; Wu W; Shi J; Zhang J; Huang W; Xie W; Luo Y; Xue X; Lin M; Huang H; Cai Z
Leuk Res; 2009 Dec; 33(12):1615-8. PubMed ID: 19773080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]